After an monitoring committee announced that the prostate cancer trial should continue, the EXEL stock dropped 40%. The market expected the trial to be stopped early for good results.
Apparently, patients in the control group taking prednisone, switched out to some of the other new drugs messing up the trial data analysis. Progenics will have to deal with this type of problem in their PMSA-ADC trial. The three new PC drugs on the market will make it difficult to conduct a clean trial for the 4th and 5th new drugs.